Synthetic Inhibitors of Prolyl Endopeptidase Exhibit Antidepressant-Like Effects in Rat Models of Depressive Syndrome and Anxiety-Depression State

N.A. Krupina, N.N. Khlebnikova, N.N. Zolotov, E.Yu Kushnareva, N.G. Bogdanova and I.N. Orlova (Editors)
Russian Academy of Medical Sciences, Moscow, Russia

Series: Pharmacology – Research, Safety Testing and Regulation
BISAC: MED071000

Clear

$0.00

Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick

eBook

Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:

Quantity:

Details

Current theories of antidepressant action are substantially based on increasing the availability of the monoamine neurotransmitters. A new trend in antidepressant medication includes mechanisms connected with neuropeptides and peptide hormones lacking in side effects. Increasing evidence proves the involvement of neuropeptides in the development of depression and anxiety. However, there is a lack of data on the enzymes cleaving neuropeptides mediating depression and anxiety.

This new book reviews results obtained in two rat models of depression which prove that PEP inhibitors benzyloxycarbonyl-methionyl-2(S)-cyano-pyrrolidine and benzyloxycarbonyl-alanyl-proline to have antidepressant-like properties. These result promote a new approach to treatment strategy for depressive disorders based on modulation of PEP activity with synthetic inhibitors. (Imprint: Nova Biomedical)

ABSTRACT

INTRODUCTION

METHODS

RESULTS

DISCUSSION

CONCLUSION

REFERENCES

INDEX

You have not viewed any product yet.